Cancer immunotherapy can lose its punch when tumor-fighting T cells become exhausted, but researchers may have found a way to keep them going longer. Scientists at Memorial Sloan Kettering Cancer Center identified a signaling molecule called MEK that can push T cells to burn through their energy while producing cancer-killing proteins. In animal and laboratory studies, blocking MEK helped the cells conserve energy, survive longer, and remain active even in the harsh environment around tumors.